RegeneRx phase II trial on clinical hold

Tuesday, March 22, 2011

RegeneRx Biopharmaceuticals has received a notice from the FDA indicating that, due to non-compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations by its contract manufacturer, the company’s phase II clinical trial of RGN-352, its injectable formulation of Thymosin beta 4 for the treatment of acute myocardial infarction (AMI), has been placed on clinical hold.

[Read More]